Plecanatide: Phase II/III started

Synergy Pharmaceuticals Inc. (OTCQB:SGYP, New York, N.Y.) began a double-blind, placebo-controlled, U.S. Phase II/III trial (SP304-20210) to evaluate 0.3, 1 or 3 mg oral plecanatide once daily for 12...